2012- TB Laboratory Specimen Referral, Reporting & Transportation for diagnosis and management of MDR-TB (January to June 2012)

Clinical Management of MDR-TB Questionnaire-Form 3

For Official Use Only

SECTION A: IDENTIFICATION PARTICULARS

(Tick or describe the answer in the space(s) provided and leave boxes on the right for coding/official use only)

1. **PROVINCE:** _____[   ]

2. **DISTRICT:**_____[   ] [   ]

3. **HOSPITAL/HEALTH CENTRE:**_____[   ] [   ]

4. **DEPARTMENT:**_____[   ] [   ]

5. **PROFESSION OF RESPONDANT:** _____[   ]

6. **POSITION OF RESPONDANT:**_____[   ]

7. **SEX OF RESPONDANT:**   0.[ ] Female   1.[ ] Male

8. **DATE OF INTERVIEW**:____/____/2012   **NAME OF INTERVIEWER**:_____

SECTION B: STAFF PERCEPTION OF SPECIMEN REFERRAL SYSTEM

(Tick in the box (es) or give a brief description of the answer in the space(s) provided)

Q1.Is the specimen referral system in place? Yes   No

Q2. How would you rate the level of satisfaction with the specimen referral system?

1.[ ]Excellent
2.[ ]Good
3.[ ]Satisfactory
4.[ ]Fair
5.[ ]Poor

Q3. Are results available when needed?   0.[ ] Yes 1.[ ] No

Q4. Has the specimen referral improved patients' attendance?   0.[ ] Yes 1.[ ] No

Q5. Has the specimen referral reduced defaulter rates?   0.[ ] Yes 1.[ ] No
Q6. Is there an interaction between the laboratory staff and clinicians/PMDT?

0.[ ] Yes 1.[ ] No*>>Go to next section*

Q7. If yes, what is the main mode of this interaction?

1.[ ] Workshop
2.[ ] Regular in-house meetings
3.[ ] Correspondence
4.[ ] Bulletins/publication
5.[ ] Other specify_____

Q8. What is the number of MDR-TB cases with primary drug resistance identified per month 6 months? [.........]

Q9. What is the number of MDR-TB cases with secondary drug resistance identified per 6 months ? [.........]

Q10. What is the number of patients/referral cases started on 2nd line treatment [.........]

SECTION C: CHALLENGES FOR DIAGNOSIS AND MANAGEMENT OF MDR-TB

(Give a brief description for the answer in the space(s) provided)

Q1. What is the funding mechanism for the specimen referral system? (Explain briefly)

_____

_____

_____

Q2. What are the challenges if any of the specimen referral system? *(Briefly explain)*

_____

_____

Q3. What improvements would you like to see to the specimen referral system? *(Briefly explain)*

_____

_____

Q4. What are the challenges and constraints to diagnosing and treating MDR TB cases (including availability of 2nd line drugs for the numbers diagnosed)? *(Briefly explain)*

_____

_____

Q5. What is your current status of implementing of PMDT/ NTP policies and guidelines on MDR TB diagnosis and management? *(Briefly explain)*

_____

_____

Q6. Is there a need for improvement and capacity building in the implementation of the PMDT guidelines? 0.[ ] Yes   1.[ ] No

(Briefly explain)

_End of Interview!

THANK YOU FOR YOUR INFORMATION AND TIME